The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis

Dvora Sredni-Kenigsbuch*, Michael Shohat, Batia Shohat, Dan Ben-Amitai, Chi Chao Chan, Michael David

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

16 Scopus citations

Abstract

The immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.

Original languageEnglish
Pages (from-to)232-235
Number of pages4
JournalJournal of Dermatological Science
Volume50
Issue number3
DOIs
StatePublished - Jun 2008
Externally publishedYes

Funding

FundersFunder number
National Institutes of HealthZ01EY000222

    Fingerprint

    Dive into the research topics of 'The novel tellurium immunomodulator AS101 inhibits interleukin-10 production and p38 MAPK expression in atopic dermatitis'. Together they form a unique fingerprint.

    Cite this